Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?

The stock rallied after the FDA indicated that it would convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee to review the company's new drug application (NDA) for pipeline candidate arimoclomol. The NDA is seeking approval for arimoclomol as an orally delivered, first-in-class treatment for Niemann-Pick disease type C. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> While earnings an ...